Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Remuneration Information 2018

Nov 27, 2018

5262_rns_2018-11-27_a19ef3f7-21d4-4f76-bb7f-9ed3eef1abb1.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6693I

GlaxoSmithKline PLC

27 November 2018

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan
Period of return: From: 1 May 2018 To: 31 October 2018
Balance of unallotted securities under scheme(s) from previous return: Previous balance: 33,863*

Restated balance: -27,669
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 575,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 547,331
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

*Due to clerical error the opening balance has been restated.

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return: From: 1 May 2018 To: 31 October 2018
Balance of unallotted securities under scheme(s) from previous return: Previous balance: 2,693,951*

Restated balance: 2,755,483
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 532,131
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 2,223,352
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

*Due to clerical error the opening balance has been restated.

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Share Option Plan - ADS
Period of return: From: 1 May 2018 To: 31 October 2018
Balance of unallotted securities under scheme(s) from previous return: 7,909,994
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 573,898
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 7,336,096
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc Share Save Plan 2012
Period of return: From: 1 May 2018 To: 31 October 2018
Balance of unallotted securities under scheme(s) from previous return: 827,306
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 5,000,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 154,683
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 5,672,623
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRZMMZMKNZGRZM